The Liposome Company Evacet Phase III Results Will Support December Filing
Executive Summary
An NDA for The Liposome Company's liposomal doxorubicin will be submitted in a few weeks, the company said after data from three Phase III trials were presented Nov. 10 in Athens, Greece. Evacet (formerly TLC D-99) will be submitted for first-line treatment of metastatic breast cancer.